Intervention not reported
Days at risk of transmitting the infection into the community
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Duration of mechanical ventilation · neonates with mechanical ventilation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of mechanical ventilation · neonates with mechanical ventilation
1 finding from 1 review
Duration of mechanical ventilation · neonates with mechanical ventilation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of mechanical ventilation · neonates with mechanical ventilation
1 finding from 1 review
Duration of mechanical ventilation · neonates with mechanical ventilation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of mechanical ventilation · neonates with mechanical ventilation
1 finding from 1 review
Number of wheezing days · children (0 to 24 months)
Palivizumab leads to lower number of wheezing days compared with placebo, no intervention or standard care (high certainty).
1 finding from 1 review
Surgical complications, serious (up to 90 days; MCID 2%) · patients with non‐muscle invasive bladder cancer
Blue light showed no clear difference in surgical complications, serious (up to 90 days; MCID 2%) compared with white light (low certainty).
1 finding from 1 review
Any adverse events (up to 90 days; MCID 5%) · patients with non‐muscle invasive bladder cancer
Blue light showed no clear difference in any adverse events (up to 90 days; MCID 5%) compared with white light (low certainty).
1 finding from 1 review
Surgical complications, non‐serious (up to 90 days; MCID 5%) · patients with non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 30 · non‐hospitalised individuals with COVID‐19
1 finding from 1 review
Mortality by day 60 ‐ not reported · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 60 · non‐hospitalised individuals with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab showed no clear difference in mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found